Kinnate jumps onto the biotech stage with $74.5M and a fledgling cancer drug pipeline
Cancer continues to be the disease category of choice among a large swath of biotech VCs.
San Diego-based Kinnate has jumped out from the shadows with a hefty $74.5 million B round to fund its work on developing a new pipeline of kinase inhibitors. Their small molecule discovery approach has centered on a lead effort aimed at DNA damage repair pathways — think PARP here — with followup programs targeting gene “rearrangement” with known mutations and a third effort on an unspecified pathway.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
